Dendreon Option Premiums Remain Astronomical (DNDN)
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
From 247WallSt
Dendreon (NASDAQ: DNDN) has only up to 4 full trading before that May 15 FDA review date. The funny thing here is that the options have actually become more expensive since reporting on this last week. The current $17.50 straddle would run $12.90 for the May expiration on the Put and Call strike prices.
Even going way out on the strikes is far from a bargain: The May $25.00 Calls went out at $3.80 premium today; and the May $10.00 Puts went out at $2.10. Neither of those are cheap at a $17.74 close for Dendreon today. The funniest thing is that the time value portion of the premiums will not compress drastically each day ahead of the FDA event as more and more traders have little to no choice but to put on certain hedging transactions after the last move that Dendreon made on receipt of the panel backing for provenge. If this was a normal option with no event risk it would theoretically lose up to 1/8 of the value each day from here, but the event risk going into next Wednesday will keep these premiums high until after the formal FDA decision.
There is still a ways to go before (5 trading days) this one is a known verdict.
Jon C. Ogg
For more market insight go to http://www.247wallst.com/
Dendreon (NASDAQ: DNDN) has only up to 4 full trading before that May 15 FDA review date. The funny thing here is that the options have actually become more expensive since reporting on this last week. The current $17.50 straddle would run $12.90 for the May expiration on the Put and Call strike prices.
Even going way out on the strikes is far from a bargain: The May $25.00 Calls went out at $3.80 premium today; and the May $10.00 Puts went out at $2.10. Neither of those are cheap at a $17.74 close for Dendreon today. The funniest thing is that the time value portion of the premiums will not compress drastically each day ahead of the FDA event as more and more traders have little to no choice but to put on certain hedging transactions after the last move that Dendreon made on receipt of the panel backing for provenge. If this was a normal option with no event risk it would theoretically lose up to 1/8 of the value each day from here, but the event risk going into next Wednesday will keep these premiums high until after the formal FDA decision.
There is still a ways to go before (5 trading days) this one is a known verdict.
Jon C. Ogg
For more market insight go to http://www.247wallst.com/
You May Also Be Interested In
- SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
- OpenAI proposes handing Trump administration a 5% stake, FT reports
- Apple negotiates with blacklisted Chinese chipmakers amid AI-driven memory crunch
Create E-mail Alert Related Categories
ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
